**Table S1. Inclusion and Exclusion Criteria**.

|  |  |
| --- | --- |
| **Inclusion criteria** | **Exclusion criteria** |
| Caribbean Hispanics residing in Puerto Rico  Both genders (males/females)  Age ≥ 21  Receiving clopidogrel (75 mg/day) for these therapeutic indications: ACS, CAD, and PAD. #  No clinically active hepatic abnormality.  The ability to understand the requirements of the study.  The ability to comply with the study procedures and protocols.  A female patient is eligible to enter the study if she is of child-bearing potential and not pregnant or nursing, or not of child-bearing potential. | Non-Hispanic patients  Currently enrolled in another active research protocols  Other therapeutic indications#  BUN > 30 and creatinine > 2.0mg/dL  Hematocrit (Hct) ≤ 25%  Nasogastric or enteral feedings  Acute illness (e.g., sepsis, infection, anemia)  HIV/AIDS, Hepatitis B patients  Alcoholism and drug abuse  Patients with any cognitive and mental health impairment  Sickle cell patients  Active malignancy  Patients taking another antiplatelet |

#Since less than 5% of the participants in the study cohort received clopidogrel for indications other than ACS, CAD or PAD (i.e., a stroke or transient ischemic attacks (TIA)), we decided not to include these patients in further analyses. Furthermore, the role of genomics and, in particular, the impact of specific genetic markers on clopidogrel response in stroke patients is less well understood [55].